SingHealth Duke-NUS clinicians Assoc Prof Lim Boon Leng and Assoc Prof Toh Han Chong were awarded at the National Medical Excellence Awards (NMEA) 2018.
SingHealth Duke-NUS clinicians Assoc Prof Lim Boon Leng and Assoc Prof Toh Han Chong were awarded at the National Medical Excellence Awards (NMEA) 2018 on 16 August 2018, along with three other clinicians and two teams from across Singapore’s public healthcare.
NMEA is a national award that recognises healthcare professionals for their contributions in advancing healthcare, improving the standards of patient safety and quality of care.
Find out more about SingHealth Duke-NUS’ winners, and why they are indeed deserving of the recognition…
“For his dedication and passion in pushing the boundaries of postgraduate medical education and training; and for his outstanding leadership in creating an environment for teaching and learning.”
Assoc Prof Lim Boon Leng has been an anaesthesiologist for nearly three decades. He has almost as many years of experience as an educator, teaching clinicians and raising the bar of medical education. Many students and clinicians think of him as an encouraging and patient mentor who is always available to provide support.
He was one of the pioneers of a course which has been running for 18 years to train anaesthesiologists, respiratory and emergency physisians, nurses and allied health professionals involved in the care of ICU patients.
Assoc Prof Lim led SingHealth Residency until 2018, where he attained the accreditation for all 34 SingHealth Residency programmes. He established an online course to help the Residency faculty teach, and introduced the SingHealth Residency Leadership Programme to build a pipeline of leaders among the residents.
Watch Assoc Prof Lim talk about his passion in medicine and teaching junior doctors here. [opens in YouTube]
“For his outstanding contributions in cancer immunotherapy which offers new hope to patients.”
Assoc Prof Toh is one of the earlierst pioneers of Cell and Cancer Immunotherapy in South East Asia and has been leading the programme for over 15 years. His work on immunotherapy is now widely regarded as one of the standard pillars of cancer treatment and was named ‘Breakthrough of the Year 2013” by Science.
With his protégé, he leads a global leading clinical trial involving 1,200 patients, exploring the role of aspirin in an adjuvant setting for colorectal cancer (ASCOLT). If shown to confer a survival benefit, the trial would have a major impact on the treatment on colorectal, saving costs and millions more lives globally.
Assoc Prof Toh is also a passionate mentor to healthcare professionals, many of which have found their own successes in their research careers.